Save 20% on your next Cambridge Bioethics and Law online purchase
Page URL: https://www.bionews.org.uk/page_150876

Saving lives with early breast and ovarian cancer screening

20 July 2020
Appeared in BioNews 1056

Screening all women over 30 for the most common breast and ovarian cancer causing mutations could prevent millions of cancer deaths worldwide, according to a new study.

A research team based at Queen Mary, University of London (QMUL) has found that testing all women over 30 for mutations in the BRCA genes could prevent millions of deaths from breast and ovarian cancer, as well as proving cost-effective in middle and high-income countries. In the UK, the researchers model that this approach could save almost 12,000 lives.

Professor Ranjit Manchanda, lead author on the study, said: 'General population BRCA testing can bring about a new paradigm for improving global cancer prevention. Why do we need to wait for people to develop a preventable cancer to identify others in whom we can prevent cancer?'

Mutations in the BRCA gene cause ten to 20 percent of ovarian and six percent of breast cancers. Identifying carriers before they develop disease can lead to early detection and/or prevention of breast and ovarian cancer through increased screening, drugs and preventative surgery. Current guidelines only recommend testing 'high-risk' potential carriers for BRCA mutations: women who have a strong family history of breast or ovarian cancer. However, 50 percent of BRCA mutation carriers do not meet the current testing criteria, and over 97 percent of BRCA mutation carriers in the UK remain unidentified.  

'Strategies and pathways for population testing must be developed to enable population genomics to achieve its potential for maximising early detection and cancer prevention' said Professor Manchanda.

Large-scale population screening is not without risk. Baroness Delyth Morgan, chief executive of the charity Breast Cancer Now, told inews: 'Undergoing testing for genetic changes that increase your cancer risk can be a very anxious process for many, which would need to be carefully considered, including identifying what additional support may need to be provided.'

Further, Professor Nora Pashayan, from the Department of Applied Health Research at University College London, who was not involved in the study, also cautioned: 'Not everyone who has BRCA1/BRCA2 mutation will eventually develop breast or ovarian cancer. Offering treatment to all risks overtreatment. This comes at financial and psychological cost. This should be accounted for.'

RELATED ARTICLES FROM THE BIONEWS ARCHIVE
10 February 2020 - by Isobel Steer 
The largest-ever study of cancer genomes, the Pan-Cancer Project, has published a collection of 23 papers as the result of a ten-year collaboration...
13 January 2020 - by Dr Marieke Bigg 
A major international study of the genetics of breast cancer published in the journal Nature Genetics has identified more than 350 genetic variants that increase an individual's risk of developing the disease...
7 October 2019 - by Dr Loredana Guglielmi 
Multigene testing for all women diagnosed with breast cancer would save thousands of lives each year in the UK and USA, suggests new research...
27 August 2019 - by Charlott Repschlager 
An influential health group in the USA has concluded that more women could benefit from wider gene screening for hereditary breast or ovarian cancer...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.